PADCEV (enfortumab vedotin-ejfv) for injectionPADCEV (enfortumab vedotin-ejfv) for injection
Quantity
Get it to Germany within 10 working days with standard delivery.
Fast delivery to Germany
Easy Returns & Exchanges
Ask About This Product
Condition : New
0
From UAE
To Germany
in 5-10 days
Description
How It Works
PADCEV works by targeting a protein called Nectin-4, which is highly expressed in urothelial cancers. Enfortumab vedotin, the active ingredient in PADCEV, binds to Nectin-4 and delivers a potent chemotherapy drug directly to cancer cells. This targeted approach helps to kill cancer cells while minimizing damage to healthy tissues.Side Effects
- Fatigue
- Nausea
- Decreased appetite
- Diarrhea
- Peripheral neuropathy (numbness or tingling in the hands or feet)
- Increased blood sugar levels
Indications
- PADCEV is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
Contraindications
- Hypersensitivity to enfortumab vedotin-ejfv or any of the excipients
- Severe renal impairment (creatinine clearance less than 30 mL/min)
- Pregnancy or breastfeeding
Price Comparison in Different Countries
| Country | Price (USD) | Reference |
|---|---|---|
| United States | $17,000.00 | GoodRx |
| United Kingdom | ?14,000.00 | NHS UK |
| Australia | $20,000.00 AUD | Pharmaceutical Benefits Scheme Australia |
| Canada | $18,000.00 CAD | MedBroadcast Canada |
Top 5 Global Brands
- Astellas Pharma
- Pfizer
- Roche
- Bristol Myers Squibb
- Merck & Co.